Your browser doesn't support javascript.
loading
Childhood eczema prevalence in New Zealand using topical corticosteroid dispensing data.
Harvey, Georgina; Purvis, Diana J; Thompson, John M D; Haskell, Libby; Kennedy, Harriet; Hoare, Karen; Dalziel, Stuart R.
Afiliação
  • Harvey G; Women's and Children's Hospital, Adelaide, South Australia, Australia.
  • Purvis DJ; Starship Children's Hospital, Te Whatu Ora Auckland, Auckland, New Zealand.
  • Thompson JMD; University of Auckland, Auckland, New Zealand.
  • Haskell L; Starship Children's Hospital, Te Whatu Ora Auckland, Auckland, New Zealand.
  • Kennedy H; University of Auckland, Auckland, New Zealand.
  • Hoare K; University of Auckland, Auckland, New Zealand.
  • Dalziel SR; Auckland City Hospital, Te Whatu Ora Auckland, Auckland, New Zealand.
Australas J Dermatol ; 2024 Jul 14.
Article em En | MEDLINE | ID: mdl-39003644
ABSTRACT

OBJECTIVES:

To determine the prevalence of eczema among children in New Zealand.

METHODS:

Population-based retrospective observational study utilising national pharmaceutical dispensing records for topical corticosteroids and emollients for all New Zealand children aged 0-14 years from 1st January 2006 to 31st December 2019. Data are reported using descriptive statistics, with comparisons between ethnicities and socioeconomic quintiles undertaken with rate ratios.

RESULTS:

Based on dispensing data, the prevalence of eczema for New Zealand children aged 0-14 years in 2018 was 14.0% (95% CI 14.0%-14.1%), with prevalence decreasing in older age groups (children aged <1 year 26.0% (25.6%-26.4%); children aged 10-14 years 8.8% (8.7%-8.9%)). Prevalence was higher in Pacific children (23.6% (23.3%-24.0%)), but slightly lower in Maori children (13.2% (13.0%-13.3%)).

CONCLUSION:

Eczema is a common condition affecting a considerable proportion of children in New Zealand. This study provides nationwide paediatric prevalence data for New Zealand, and highlights the increased burden of eczema in Pacific children. Inequity in dispensing of topical corticosteroids is postulated to explain the reduced rates found for Maori children compared to previous studies. These results support the need for further research to determine factors contributing to differing eczema prevalence rates in New Zealand.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Australas J Dermatol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Australas J Dermatol Ano de publicação: 2024 Tipo de documento: Article